GlassScriptPhysician profile
James P Rice
NPI 1376547794
$3,146.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,570 · 2020: $452 · 2021: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,061.84 | 2019 | |
| Femselect INC. | $434.39 | 2020 | |
| Boston Scientific Corporation | $160.90 | 2019-2021 | |
| Coopersurgical, INC. | $139.53 | 2019 | |
| Astellas Pharma US INC | $114.81 | 2019-2020 | |
| Stryker Corporation | $112.00 | 2019 | |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Coloplast Corp | $32.82 | 2019 | |
| Abbott Laboratories | $22.28 | 2021 | |
| Pfizer INC. | $16.04 | 2019 | |
| Therapeuticsmd, INC. | $12.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.